Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Mod Rheumatol ; 17(2): 144-7, 2007.
Article in English | MEDLINE | ID: mdl-17437170

ABSTRACT

Relapsing polychondritis (RP) is a rare disease of unknown etiology causing systematic inflammation and resulting in destruction of cartilaginous tissues. We describe here an 18-year-old Japanese woman who developed severe airway stenosis as the initial symptom with auricular, nasal, and ocular inflammation. The effect of high dose oral steroid, methylprednisolone pulse therapy, and cyclophosphamide was temporary and her conditioning was worsening. Finally we added methotrexate to the immunosuppressive treatment and achieved reduction of disease activity. This case illustrates the potentially fatal sudden onset of airway inflammation that can occur with this disorder, and the effectiveness of methotrexate.


Subject(s)
Cyclophosphamide/therapeutic use , Immunosuppressive Agents/therapeutic use , Methotrexate/therapeutic use , Polychondritis, Relapsing/drug therapy , Adolescent , Antirheumatic Agents/therapeutic use , Drug Therapy, Combination , Female , Humans , Inflammation/etiology , Methylprednisolone/therapeutic use , Polychondritis, Relapsing/diagnostic imaging , Tomography, X-Ray Computed
2.
Ann Rheum Dis ; 66(4): 470-5, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17107983

ABSTRACT

AIM: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious treatment-resistant phenotype of systemic lupus erythematosus. A standard treatment for NPSLE is not available. This report describes the clinical and laboratory tests of 10 patients with NPSLE before and after rituximab treatment, including changes in lymphocyte phenotypes. METHODS: Rituximab was administered at different doses in 10 patients with refractory NPSLE, despite intensive treatment. RESULTS: Treatment with rituximab resulted in rapid improvement of central nervous system-related manifestations, particularly acute confusional state. Rituximab also improved cognitive dysfunction, psychosis and seizure, and reduced the SLE Disease Activity Index Score at day 28 in all 10 patients. These effects lasted for >1 year in five patients. Flow cytometric analysis showed that rituximab down regulated CD40 and CD80 on B cells and CD40L, CD69 and inducible costimulator on CD4+ T cells. CONCLUSIONS: Rituximab rapidly improved refractory NPSLE, as evident by resolution of various clinical signs and symptoms and improvement of radiographic findings. The down regulation of functional molecules on B and T cells suggests that rituximab modulates the interaction of activated B and T cells through costimulatory molecules. These results warrant further analysis of rituximab as treatment for NPSLE.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD20/blood , Lupus Vasculitis, Central Nervous System/drug therapy , Adult , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Murine-Derived , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Female , Humans , Immunophenotyping , Lupus Vasculitis, Central Nervous System/immunology , Lymphocyte Depletion/methods , Lymphocyte Subsets/drug effects , Lymphocyte Subsets/immunology , Middle Aged , Rituximab , Severity of Illness Index , Treatment Outcome
3.
Clin Immunol ; 119(3): 297-306, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16503201

ABSTRACT

Systemic lupus erythematosus (SLE) presents various clinical features; however, underlying mechanisms remain unclear. In the immunity of SLE, impaired T cell receptor (TCR) signaling and altered cytokine production are in the center of pathogenesis, although, little is known about NFAT (nuclear factor of activated T cells) in lupus T lymphocytes. TCR stimulation activates NFAT1 through Ca2+/calcineurin (Cn) pathway, facilitating nuclear translocation of NFAT1 from cytosol. Therefore, we investigated relationship of disease activity/features and intracellular NFAT1 localization in T lymphocytes from active lupus patients by fractionation. Results showed no significant relationship between disease activity and NFAT1 distribution. However, interestingly, we observed skewed NFAT1 distribution in pellet in patients with active lupus nephritis or pleuritis. In vitro cyclosporin A treatment suggested autonomously activated Ca2+/Cn pathway in lupus T lymphocytes. Considering these results, NFAT1 might be presenting the clinical heterogeneity in SLE.


Subject(s)
Lupus Erythematosus, Systemic/metabolism , NFATC Transcription Factors/metabolism , T-Lymphocytes/metabolism , Adult , Aged , Cyclosporine/pharmacology , Female , Humans , I-kappa B Proteins/metabolism , Male , Middle Aged , T-Lymphocytes/drug effects
4.
J Bone Miner Res ; 19(1): 165-7, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14753748

ABSTRACT

We experienced a 57-year-old female with adult-onset non-congenital idiopathic acro-osteolysis combined with proximal symphalangism. At the age of 36, she developed severe pain and swelling of the toe base of both feet and underwent Clayton surgery. However, the size of her toes diminished progressively over the 5-year period after surgery. At the age of 41, she suffered pain and swelling of the proximal interphalangeal (PIP) joints of fingers of both hands. These PIP joints became rigid and inflexible. Subsequently, she noticed shortening of the little finger of both hands, followed later by shortening of the index, middle, and ring fingers. At the age of 57, the thumbs began to shorten. Laboratory and endocrinological examinations were not abnormal. Finally, we diagnosed her with acro-osteolysis combined with proximal symphalangism by radiological examination. In this case, previously unreported mutations of the Noggin gene were identified. This is the first case report of adult-onset, non-congenital idiopathic acro-osteolysis combined with proximal symphalangism.


Subject(s)
Acro-Osteolysis/complications , Foot Deformities, Acquired/complications , Hand Deformities, Acquired/complications , Acro-Osteolysis/diagnosis , Acro-Osteolysis/pathology , Age of Onset , Carrier Proteins , Etidronic Acid/therapeutic use , Female , Finger Joint/pathology , Foot Deformities, Acquired/diagnosis , Foot Deformities, Acquired/pathology , Hand Deformities, Acquired/diagnosis , Hand Deformities, Acquired/pathology , Humans , Middle Aged , Mutation, Missense/genetics , Proteins/genetics , Sequence Deletion/genetics , Toe Joint/pathology
5.
Clin Calcium ; 12(8): 1176-81, 2002 Aug.
Article in Japanese | MEDLINE | ID: mdl-15775417
SELECTION OF CITATIONS
SEARCH DETAIL
...